{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T23:30:18Z","timestamp":1793662218472,"version":"4.5.1"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","ejradiology.com","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Radiology"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.ejrad.2024.111772","type":"journal-article","created":{"date-parts":[[2024,10,2]],"date-time":"2024-10-02T15:46:20Z","timestamp":1727883980000},"page":"111772","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Prediction of PD-L1 expression in unresectable hepatocellular carcinoma with gadoxetic acid-enhanced MRI"],"prefix":"10.1016","volume":"181","author":[{"given":"Jun Gu","family":"Kang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyunghwa","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taek","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyungjin","family":"Rhee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"15","key":"10.1016\/j.ejrad.2024.111772_b0005","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1056\/NEJMra1713263","article-title":"Hepatocellular carcinoma","volume":"380","author":"Villanueva","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"25","key":"10.1016\/j.ejrad.2024.111772_b0010","doi-asserted-by":"crossref","first-page":"3994","DOI":"10.1200\/JCO.2010.28.7805","article-title":"Hepatocellular carcinoma: consensus recommendations of the National Cancer Institute clinical trials planning meeting","volume":"28","author":"Thomas","year":"2010","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.ejrad.2024.111772_b0015","doi-asserted-by":"crossref","first-page":"252","DOI":"10.3350\/cmh.2023.0099","article-title":"Overview of Asian clinical practice guidelines for the management of hepatocellular carcinoma: an Asian perspective comparison","volume":"29","author":"Cho","year":"2023","journal-title":"Clin. Mol. Hepatol."},{"issue":"3","key":"10.1016\/j.ejrad.2024.111772_b0020","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.jhep.2021.11.018","article-title":"BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update","volume":"76","author":"Reig","year":"2022","journal-title":"J. Hepatol."},{"issue":"2","key":"10.1016\/j.ejrad.2024.111772_b0025","doi-asserted-by":"crossref","first-page":"316","DOI":"10.17998\/jlc.2023.09.04","article-title":"A multidisciplinary approach with immunotherapies for advanced hepatocellular carcinoma","volume":"23","author":"Lee","year":"2023","journal-title":"J. Liver Cancer"},{"issue":"20","key":"10.1016\/j.ejrad.2024.111772_b0030","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.ejrad.2024.111772_b0035","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2100070","article-title":"Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma","volume":"1","author":"Abou-Alfa","year":"2022","journal-title":"NEJM Evid."},{"issue":"3","key":"10.1016\/j.ejrad.2024.111772_b0040","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/s41568-019-0116-x","article-title":"The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy","volume":"19","author":"Havel","year":"2019","journal-title":"Nat. Rev. Cancer"},{"issue":"11","key":"10.1016\/j.ejrad.2024.111772_b0045","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1038\/s41571-023-00816-4","article-title":"Biomarkers for immunotherapy of hepatocellular carcinoma","volume":"20","author":"Greten","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.ejrad.2024.111772_b0050","doi-asserted-by":"crossref","first-page":"9282","DOI":"10.1002\/cam4.5676","article-title":"The predictive value of PD-L1 expression in patients with advanced hepatocellular carcinoma treated with PD-1\/PD-L1 inhibitors: a systematic review and meta-analysis","volume":"12","author":"Yang","year":"2023","journal-title":"Cancer Med."},{"issue":"10","key":"10.1016\/j.ejrad.2024.111772_b0055","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.3390\/diagnostics11101875","article-title":"Assessing PD-L1 expression level via preoperative MRI in HCC based on integrating deep learning and radiomics features","volume":"11","author":"Tian","year":"2021","journal-title":"Diagnostics"},{"issue":"7","key":"10.1016\/j.ejrad.2024.111772_b0060","doi-asserted-by":"crossref","first-page":"3759","DOI":"10.1007\/s00330-020-06675-2","article-title":"MRI radiomics features predict immuno-oncological characteristics of hepatocellular carcinoma","volume":"30","author":"Hectors","year":"2020","journal-title":"Eur. Radiol."},{"issue":"1","key":"10.1016\/j.ejrad.2024.111772_b0065","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-023-34763-y","article-title":"Radiomics models based on multisequence MRI for predicting PD-1\/PD-L1 expression in hepatocellular carcinoma","volume":"13","author":"Gong","year":"2023","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.ejrad.2024.111772_b0070","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s00262-021-02957-w","article-title":"Imaging features of gadoxetic acid-enhanced MR imaging for evaluation of tumor-infiltrating CD8 cells and PD-L1 expression in hepatocellular carcinoma","volume":"71","author":"Sun","year":"2022","journal-title":"Cancer Immunol. Immunother."},{"issue":"1","key":"10.1016\/j.ejrad.2024.111772_b0075","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.jhep.2020.08.013","article-title":"Gadoxetic acid-enhanced MRI of macrotrabecular-massive hepatocellular carcinoma and its prognostic implications","volume":"74","author":"Rhee","year":"2021","journal-title":"J. Hepatol."},{"issue":"2","key":"10.1016\/j.ejrad.2024.111772_b0080","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1148\/radiol.15142394","article-title":"Single hepatocellular carcinoma: preoperative MR imaging to predict early recurrence after curative resection","volume":"276","author":"An","year":"2015","journal-title":"Radiology"},{"issue":"12","key":"10.1016\/j.ejrad.2024.111772_b0085","doi-asserted-by":"crossref","first-page":"3877","DOI":"10.1016\/j.ejrad.2012.07.021","article-title":"Hyperintense HCC on hepatobiliary phase images of gadoxetic acid-enhanced MRI: correlation with clinical and pathological features","volume":"81","author":"Kim","year":"2012","journal-title":"Eur. J. Radiol."},{"issue":"2","key":"10.1016\/j.ejrad.2024.111772_b0090","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1007\/s00330-022-09105-7","article-title":"Comparison of imaging findings of macrotrabecular-massive hepatocellular carcinoma using CT and gadoxetic acid-enhanced MRI","volume":"33","author":"Cha","year":"2023","journal-title":"Eur. Radiol."},{"issue":"6","key":"10.1016\/j.ejrad.2024.111772_b0095","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1002\/hep.28710","article-title":"Programmed death ligand 1 expression in hepatocellular carcinoma: relationship With clinical and pathological features","volume":"64","author":"Calderaro","year":"2016","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.ejrad.2024.111772_b0100","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s00262-020-02691-9","article-title":"Coexpression of CMTM6 and PD-L1 as a predictor of poor prognosis in macrotrabecular-massive hepatocellular carcinoma","volume":"70","author":"Liu","year":"2021","journal-title":"Cancer Immunol. Immunother."},{"issue":"1","key":"10.1016\/j.ejrad.2024.111772_b0105","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1159\/000488540","article-title":"Hepatocellular carcinoma with irregular rim-like arterial phase hyperenhancement: more aggressive pathologic features","volume":"8","author":"Rhee","year":"2019","journal-title":"Liver Cancer"},{"issue":"9","key":"10.1016\/j.ejrad.2024.111772_b0110","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1038\/modpathol.2016.111","article-title":"Poor outcome of hepatocellular carcinoma with stemness marker under hypoxia: resistance to transarterial chemoembolization","volume":"29","author":"Rhee","year":"2016","journal-title":"Mod. Pathol."},{"issue":"1","key":"10.1016\/j.ejrad.2024.111772_b0115","doi-asserted-by":"crossref","first-page":"143","DOI":"10.17998\/jlc.2023.02.16","article-title":"Radiologic features of hepatocellular carcinoma related to prognosis","volume":"23","author":"Hwang","year":"2023","journal-title":"J. Liver Cancer"},{"key":"10.1016\/j.ejrad.2024.111772_b0120","doi-asserted-by":"crossref","unstructured":"A. Korean Liver Cancer, K. National Cancer Center, 2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma, Korean J. Radiol. 23(12) (2022) 1126-1240.","DOI":"10.3348\/kjr.2022.0822"}],"container-title":["European Journal of Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0720048X24004881?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0720048X24004881?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T17:12:55Z","timestamp":1738429975000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0720048X24004881"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":24,"alternative-id":["S0720048X24004881"],"URL":"https:\/\/doi.org\/10.1016\/j.ejrad.2024.111772","relation":{},"ISSN":["0720-048X"],"issn-type":[{"value":"0720-048X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prediction of PD-L1 expression in unresectable hepatocellular carcinoma with gadoxetic acid-enhanced MRI","name":"articletitle","label":"Article Title"},{"value":"European Journal of Radiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejrad.2024.111772","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"111772"}}